Navigation Links
NYU Steinhardt researchers to study why male millennials risk HIV transmission
Date:4/28/2014

The number of new HIV infections in the United States had remained steady in recent years, but rates among urban millennial gay, bisexual, and other young men who have sex with men (YMSM) have steadily increased in the past decade.

New York University researchers, led by Perry Halkitis, a professor at the Steinhardt School of Culture, Education, and Human Development, the Global Institute of Public Health, and NYU Langone Medical Center, will study this population in order to better understand the reasons for this increase under a five-year, $3.1 million grant from the National Institute on Drug Abuse, part of the National Institutes of Health.

The research is a continuation of a study of young men that began in 2009 under the name Project 18 (P18).

"The goal of this project is to understand why a new generation of YMSM place themselves at risk for HIV transmission," explains Halkitis, who is also associate dean for academic affairs at NYU's Global Institute of Public Health. "We aim to understand why some men exhibit risky behaviors as they emerge into adulthood while others do not."

The project's other researchers include three faculty in NYU Steinhardt's Public Health programFarzana Kapadia, the primary co-investigator, Danielle Ompad, and Rafael Perez Figueroaas well as Richard Greene, an assistant professor at NYU Langone Medical Center.

YMSM include not only gay men, but also those who are bisexual and heterosexual men but who have had sex with other men but do not identify as gay or bisexual.

Under the grant, the research team will continue its cohort study of nearly 600 racially, ethnically, and socioeconomically diverse YMSM that began when the subjects were in their late teens and who are now in their early 20s. The study will also expand this cohort and recruit some 300 additional men who are also now in their early 20s.

The study will consider several factors that may explain the rise
'/>"/>

Contact: James Devitt
james.devitt@nyu.edu
212-998-6808
New York University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. More alcohol and traffic laws mean fewer traffic deaths, NYU Steinhardt study concludes
2. Researchers generate immunity against tumor vessel protein
3. Researchers at LSTM part of the international team to sequence the tsetse genome
4. Oxygen diminishes the hearts ability to regenerate, researchers discover
5. Finnish team of researchers finds a mutation in a tumor of the jaw
6. Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches
7. Life stressors trigger neurological disorders, researchers find
8. Penn researchers find link between sleep and immune function in fruit flies
9. Penn Medicine researchers uncover hints of a novel mechanism behind general anesthetic action
10. CU researchers discover target for treating dengue fever
11. BUSM researchers find anti-seizure drug may reduce alcohol consumption
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... ... communication management solutions, has announced the release of Service Pack 5600 for ... includes a number of enhancements to the already robust capabilities of the ...
(Date:7/7/2015)... ... July 07, 2015 , ... CareSync proudly announces ... recognized by the White House as a “Champion of Change” for Precision Medicine ... Initiative, the Champions of Change program recognizes Gleason and eight other extraordinary individuals ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... stages of drug discovery. iPSCs are generated from adult cells, such as blood ... cell type in the human body. , iPSC-derived cardiomyocytes have ...
(Date:7/6/2015)... ... July 06, 2015 , ... In order to ... American Orthopaedic Society for Sports Medicine ( AOSSM ) will present ten research ... As a leader in orthopaedic sports medicine, AOSSM annually provides more than ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... year for aesthetic reasons, which is why liposuction regularly ranks among the top ... however, fat reduction has become more than a way to slim down a ...
Breaking Medicine News(10 mins):Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 3Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 4Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 5Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 6Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3
... of the,nation,s largest providers of emergency department (ED) management ... in Berwyn,Ill., to run its ED starting Jan. 1, ... in 1975 by ED physicians driven to improve the ... CEP America focuses solely on,developing ED solutions for hospitals ...
... ASHP Midyear Clinical,Meeting and Exhibition -- Omnicell, ... provider of,system solutions to acute healthcare facilities, and ... Harvard Medical School located in,the heart ... the,planned installation of Omnicell,s SinglePointe(TM) automated patient-specific,medication management ...
... food costs, many,families are economizing on groceries but one ... about 25 cents per 8-ounce glass, on a gallon ... other beverage option in the,supermarket -- providing key vitamins ... for the entire family. To ensure moms don,t cut ...
... that Dr. Jonathan White will join the Company as head ... 8, 2008. In this role, Dr. White will have ... products to complement Haemonetics, blood management solutions portfolio. , ... CEO, said, "As the global leader in blood management solutions ...
... Maine, Dec. 8 IDEXX Laboratories, Inc. (Nasdaq: ... E. Brown, PhD as Corporate Vice President, Instrument Research ... Brown will oversee instrument development, manufacturing, and the worldwide ... "Bill,s extensive R&D and manufacturing management experience is distinctively ...
... Inc. (Nasdaq: HGSI ) today announced that it will sponsor ... 3 trial of Albuferon(R) (albinterferon alfa-2b) in chronic hepatitis C. , ... , The conference call will be hosted by ... 8:15 am Eastern Time. , , Investors ...
Cached Medicine News:Health News:CEP America Partners With MacNeal Hospital to Provide Emergency Department Management, Staffing 2Health News:Brigham and Women's Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell 2Health News:Brigham and Women's Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell 3Health News:Milk is One Beverage Jackson Can't Afford to Keep Off the Grocery List 2Health News:Milk is One Beverage Jackson Can't Afford to Keep Off the Grocery List 3Health News:Dr. Jonathan White Joins Haemonetics as Head of Research and Development 2Health News:IDEXX Laboratories Names William Brown Corporate Vice President 2Health News:Human Genome Sciences to Sponsor Conference Call 2
(Date:7/6/2015)... July 6, 2015 Array BioPharma,s (NASDAQ: ... this past weekend at the 2015 ESMO World ... At the meeting, data were shared from a ... 100-patient randomized Phase 2 expansion of that trial ... EGFR inhibitor, with or without the addition of ...
(Date:7/6/2015)... 6, 2015 Akcea Therapeutics, a wholly-owned ... ), announced today that the U.S. Food and ... volanesorsen (ISIS-APOCIII Rx ) for the treatment of ... a rare genetic disease characterized by extremely high ... Phase 2 study published in the NEJM in ...
(Date:7/4/2015)... BARCELONA , España, July 4, 2015 /PRNewswire/ ... SIR-Spheres® Y-90 a la quimioterapia de primera línea ... en el hígado (mCRC) extiende la supervivencia libre ... pacientes con cáncer colorrectal metastásico no resecable (mCRC) ... la mayor mejora en la supervivencia libre de ...
Breaking Medicine Technology:Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 2El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 3El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 4El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 5
... February 27 Novagali Pharma, a French,pharmaceutical ... first set of,data pertaining to Nova21027, its ... Novagali communicated about "Ocular ... conventional formulations of prostaglandin,analogues: an in vivo ...
... /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: ... of its new drug application ("NDA") for AFRESA(R), an ultra ... As previously announced, our internal goal was to submit the ... end of February. Based on editorial decisions made during ...
Cached Medicine Technology:Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma 2MannKind Updates Status of NDA Submission for AFRESA 2MannKind Updates Status of NDA Submission for AFRESA 3
... determination of Ang II is ... the pharmacological effect and efficiency ... angiotensin converting enzyme inhibitors (ACE ... antagonists as well as for ...
... antigen test is a visual ... presumptive qualitative detection of Respitory ... specimens in neonatal and pediatric ... test has a built-in procedural ...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
... BD Directigen EZ RSV Test utilizes a new, ... one device for rapid RSV detection. The testing ... method whereby dried reagents have already been applied ... a two-step process, with clear-cut results shown by ...
Medicine Products: